Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Validea
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GlycoMimetics Inc announces presentation of data on Rivipansel


Monday, 14 Apr 2014 09:00am EDT 

GlycoMimetics Inc:Presented data on Rivipansel (GMI-1070) in Combination with Current FDA-approved treatment for sickle cell disease.Rivipansel is in clinical trials as potential therapy for treatment of vaso-occlusive crisis (VOC) in people with sickle cell disease.Previously it has received both Orphan Drug and Fast Track status for treatment of VOC from US FDA, and Orphan Product status in European Union. 

Latest Developments for GlycoMimetics Inc